^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CLBR001/SWI019

    i
    Other names: CLBR001/SWI019, switchable-CAR-T-cell-therapy, CLBR001 + SWI019, CLBR 001/SWI 019, CLBR-001/SWI-019
    Associations

    News

    Trials
    Company:
    AbbVie, Scripps Research Institute
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    3ms
    CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=18, Completed, Calibr, a division of Scripps Research | Active, not recruiting --> Completed
    Trial completion
    |
    CLBR001/SWI019
    10ms
    CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Calibr, a division of Scripps Research | N=36 --> 18 | Trial primary completion date: Aug 2023 --> Apr 2024
    Enrollment change • Trial primary completion date
    |
    CLBR001/SWI019
    over1year
    CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Calibr, a division of Scripps Research | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
    |
    CLBR001/SWI019
    3years
    First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019) (ASH 2021)
    Following cyclophosphamide and fludarabine lymphodepletion, patients receive a single dose of CLBR001 cells, followed by daily infusion of SWI019 for 7 days...This event subsided within 24 hours of administration of dexamethasone with no recurrence of CRS observed with continued administration of a reduced dose (50%) of SWI109, providing support for the tunability of the platform...Accrual is ongoing in dose expansion cohorts of both CLBR001 cells and SWI019 switch. Updated results will be presented at the meeting.
    P1 data • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV • CLBR001/SWI019
    4years
    CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=36, Recruiting, Calibr, a division of Scripps Research | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    CD19 (CD19 Molecule) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
    |
    CLBR001/SWI019